BNP Paribas bought a new stake in McKesson Corporation (NYSE:MCK - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 54,966 shares of the company's stock, valued at approximately $47,243,000. McKesson makes up 1.1% of BNP Paribas' holdings, making the stock its 21st biggest position.
A number of other hedge funds and other institutional investors have also modified their holdings of MCK. BlackRock Inc. acquired a new stake in McKesson during the second quarter worth $8,156,743,000. Bank of America Corp DE lifted its holdings in shares of McKesson by 2.4% in the 1st quarter. Bank of America Corp DE now owns 1,538,726 shares of the company's stock worth $1,331,552,000 after acquiring an additional 35,916 shares during the last quarter. Boston Partners lifted its holdings in shares of McKesson by 1.1% in the 3rd quarter. Boston Partners now owns 1,182,796 shares of the company's stock worth $1,014,032,000 after acquiring an additional 13,120 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of McKesson by 3.3% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 922,573 shares of the company's stock worth $697,096,000 after purchasing an additional 29,747 shares during the period. Finally, Legal & General Group Plc acquired a new stake in McKesson in the 2nd quarter valued at approximately $656,566,000. 85.07% of the stock is owned by institutional investors and hedge funds.
Recent McKesson Headlines
These are some of the MCK headlines that stood out recently:
Analyst Upgrades and Downgrades
A number of analysts have issued reports on the company. Mizuho boosted their target price on McKesson from $905.00 to $1,020.00 and gave the company a "neutral" rating in a research report on Tuesday, October 20th. Royal Bank Of Canada lifted their price objective on McKesson from $845.00 to $965.00 and gave the company a "sector perform" rating in a research note on Thursday, November 5th. UBS Group lifted their price objective on McKesson from $1,200.00 to $1,250.00 and gave the company a "buy" rating in a research note on Thursday, November 5th. Barclays boosted their price objective on McKesson from $1,000.00 to $1,235.00 and gave the company an "overweight" rating in a report on Wednesday. Finally, TD Cowen upped their target price on shares of McKesson from $1,006.00 to $1,200.00 and gave the stock a "buy" rating in a research note on Thursday, November 5th. Fifteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $1,054.12.
Get Our Latest Stock Report on McKesson
Insider Activity at McKesson
In other McKesson news, EVP Francisco Fraga sold 650 shares of the firm's stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $1,102.96, for a total transaction of $716,924.00. Following the sale, the executive vice president owned 4,414 shares of the company's stock, valued at approximately $4,868,465.44. This trade represents a 12.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO B Jr sold 111 shares of the business's stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $891.45, for a total transaction of $98,950.95. Following the sale, the chief accounting officer owned 521 shares of the company's stock, valued at $464,445.45. This represents a 17.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 2,161 shares of company stock valued at $2,242,515. 0.06% of the stock is owned by company insiders.
McKesson Stock Up 0.7%
Shares of McKesson stock opened at $1,069.31 on Friday. McKesson Corporation has a 52-week low of $723.68 and a 52-week high of $1,121.50. The company has a market capitalization of $123.46 billion, a P/E ratio of 27.50, a P/E/G ratio of 1.81 and a beta of 0.27. The company has a 50 day moving average of $974.65 and a 200 day moving average of $880.71.
McKesson (NYSE:MCK - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $11.68 earnings per share for the quarter, beating analysts' consensus estimates of $10.72 by $0.96. The business had revenue of $110.96 billion for the quarter, compared to analyst estimates of $109.90 billion. McKesson had a net margin of 1.12% and a negative return on equity of 202.94%. The company's revenue was up 7.5% on a year-over-year basis. During the same period last year, the business earned $9.86 EPS. As a group, research analysts anticipate that McKesson Corporation will post 46.09 earnings per share for the current fiscal year.
McKesson Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Monday, January 4th. Investors of record on Tuesday, December 1st will be paid a dividend of $0.94 per share. The ex-dividend date is Tuesday, December 1st. This represents a $3.76 annualized dividend and a yield of 0.4%. McKesson's payout ratio is presently 9.67%.
McKesson Company Profile
(
Free Report)
McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers. The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care. Founded in 1833, McKesson serves customers primarily in the United States and Canada.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider McKesson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and McKesson wasn't on the list.
While McKesson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.